☰

Melvin D. Yahr, MD

Affiliations: 
Mount Sinai School of Medicine New York University, New York, NY, United States 
Area:
Parkinson’s disease
Google:
"Melvin Yahr"
Mean distance: 16.18 (cluster 6)
 		SNBCP
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
Arvid Carlsson research scientist G

Children

Sign in to add trainee
Oscar Samuel Gershanik grad student Mount Sinai Hospital (Manhattan)
Oscar Samuel Gershanik grad student Mount Sinai Hospital (Manhattan)

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lieberman A, Olanow CW, Sethi K, et al. (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology. 51: 1057-62
Di Rocco A, Molinari SP, Kollmeier B, et al. (1996) Parkinson's disease: progression and mortality in the L-DOPA era. Advances in Neurology. 69: 3-11
Brannan T, Yahr MD. (1995) Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Annals of Neurology. 37: 95-8
Yahr MD. (1993) Parkinson's disease. The L-dopa era. Advances in Neurology. 60: 11-7
Yahr MD. (1993) Parkinson's disease: new approaches to diagnosis and treatment. Acta Neurologica Scandinavica. Supplementum. 146: 22-5
Hauser RA, Olanow CW, Elizan TS, et al. (1991) Early therapy for Parkinson's disease [1] Archives of Neurology. 48: 1009-1010
Brannan TS, Martinez J, Yahr MD. (1991) Re: L-Dopa in parkinson's disease Neurology. 41: 1709
Elizan TS, Yahr MD, Moros DA, et al. (1990) L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients. Advances in Neurology. 53: 431-5
Yahr MD, Elizan TS, Moros D. (1989) Selegiline in the treatment of Parkinson's disease--long term experience. Acta Neurologica Scandinavica. Supplementum. 126: 157-61
Elizan TS, Yahr MD, Moros DA, et al. (1989) Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Archives of Neurology. 46: 1280-3
See more...